RE:Amber Kanwar's 'deep' dive into CXR pricingSo, it is true that "Concordia" DID NOT INCREASE the price of the pink-eye drug at all during its ownership of AMCo since October 2015. The British Financial Times knows this full well or ought to have known this. Obviously, a bunch of fraudsters trying to add to the short and distort regime that rips off retail investors. Where is the IIROC and OSC protecting our interests? Do your job or why exist? Amber's report still does not help the damage already done by FT and chicken farmer that was aired by BNN.